Chiron Real Estate Inc.

XRN

Market cap $488M

BETHESDA, Md.--(BUSINESS WIRE)--Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), announced today that it intends to release its fourth quarter and year-end 2025 financial results after the market closes on Wednesday, February 25, 2026. The Company intends to hold a conference call to discuss those results the following day, Thursday, February 26, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief Executive Officer Mark Decker, Jr., Chief F.

BETHESDA, Md.--(BUSINESS WIRE)--Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”) today announced that the Company will change its name, effective as of 12:01 a.m., Eastern Time, on February 23, 2026, to “Chiron Real Estate Inc.” Beginning on February 23, 2026, the Company's common stock will trade on the New York Stock Exchange (the “NYSE”) under the new name, “Chiron Real Estate Inc.,” and ticker symbol “XRN.” “After spending the last six months evaluating and redefining our str.

BETHESDA, Md.--(BUSINESS WIRE)--Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), announced today that information regarding the federal income tax treatment of the dividends paid in 2025 on the Company's Common Stock and Series A Preferred Stock has been posted to the Company's website, at the following link. https://investors.globalmedicalreit.com/stock-data/dividend-tax-information Note: Data for common dividends paid in January, April and July 2025 have been adjusted to refle.

BETHESDA, Md.--(BUSINESS WIRE)--Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”) today announced that Henry Cole has notified the Board of Directors (the “Board”) that he plans to step down as a member of the Board at the end of his current term. Henry Cole's Stepping Down from Board of Directors Mr. Cole has served on the Board as an Independent Director since the Company's inception and has served at different points throughout his term as the Board's Lead Independent Director,.

Global Medical REIT offers a diversified, granular healthcare property portfolio with 95.2% occupancy and an average remaining lease term of 5.3 years. GMRE has proactively extended and staggered its debt maturities, raised $50M in Series B preferred equity, and improved balance sheet flexibility. The Series A Preferred Shares yield 7.7%, are past call, and are unlikely to be redeemed soon given current rates and refinancing costs.

Global Medical REIT offers a compelling value proposition, with an 8.9% dividend yield and a forward P/FFO of 8.3. GMRE's diversified healthcare portfolio, 95%+ occupancy, and 2.1% annual rent escalators support steady cash flows and modest growth. Management's proactive debt restructuring extends maturities, mitigating refinancing risk.

Active investors have an advantage in the REIT sector. Individual REITs often get mispriced, resulting in opportunities to earn alpha-rich returns. We highlight a clear example of that.

Global Medical REIT is rated a buy, driven by strong AFFO growth, robust dividend coverage, and sector tailwinds. GMRE redeploys capital into higher cap-rate assets, maintains low tenant concentration risk, and benefits from geographic diversification including presence in high-growth regions like Texas and Florida. Despite elevated leverage (D/E 1.50), GMRE's forward P/FFO of 8.6 is 35% below sector average, suggesting undervaluation.

We are in the midst of the biggest retail sales period of the year. Yet, investors are skeptical about bargains in the stock market. Buy a bigger income stream at cheaper prices. We discuss our top defensive picks with up to 8% yields.

BETHESDA, Md.--(BUSINESS WIRE)--Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”) today announced that Ronald Marston has notified the Board of Directors (the “Board”) that he plans to retire as a member of the Board at the end of his current term and that the Board has declared the Company's 2025 fourth quarter common and preferred dividends. Ronald Marston's Retirement from Board of Directors Mr. Marston has served on the Board since 2015 as an independent director and at differ.